Gina Manda

TL;DR: NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked.

TL;DR: This review describes the electrophilic and nonelectrophilic NRF2 activators with clinical projection in various chronic diseases and analyzes the status ofNRF2 inhibitors, which at this time provide proof of concept for blocking NRf2 activity in cancer therapy.

TL;DR: A systematic review of the cellular mediators, i.e., microglia, astroglia and endothelial cells, and the genetic and transcriptional control of inflammation in PD and the immunomodulatory role of dopamine and reactive oxygen species is provided.

TL;DR: This review is directed mainly to researchers involved in anti-cancer drug development by pointing out that redox balance is a suitable therapeutic target, either alone or in combination with other pathways of cancer cells killing.

TL;DR: It is proposed that a multi-faceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2), can be deployed against the virus.